A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS
Open Access
- 28 February 2019
- journal article
- research article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (3) , 446-452
Abstract
BACKGROUND AND PURPOSE: Disappearance of T2 lesions into CSF spaces is frequently observed in patients with MS. Our aim was to investigate temporal changes of cumulative atrophied brain T2 lesion volume and 10-year confirmed disability progression. MATERIALS AND METHODS: We studied 176 patients with relapsing-remitting MS who underwent MR imaging at baseline, 6 months, and then yearly for 10 years. Occurrence of new/enlarging T2 lesions, changes in T2 lesion volume, and whole-brain, cortical and ventricle volumes were assessed yearly between baseline and 10 years. Atrophied T2 lesion volume was calculated by combining baseline lesion masks with follow-up CSF partial volume maps. Ten-year confirmed disability progression was confirmed after 48 weeks. ANCOVA detected MR imaging outcome differences in stable (n = 76) and confirmed disability progression (n = 100) groups at different time points; hierarchic regression determined the unique additive variance explained by atrophied T2 lesion volume regarding the association with confirmed disability progression, in addition to other MR imaging metrics. Cox regression investigated the association of early MR imaging outcome changes and time to development of confirmed disability progression. RESULTS: The separation of stable-versus-confirmed disability progression groups became significant even in the first 6 months for atrophied T2 lesion volume (140% difference, Cohen d = 0.54, P = .004) and remained significant across all time points (P ≤ .007). The hierarchic model, including all other MR imaging outcomes during 10 years predicting confirmed disability progression, improved significantly after adding atrophied T2 lesion volume (R2 = 0.27, R2 change 0.11, P = .009). In Cox regression, atrophied T2 lesion volume in 0–6 months (hazard ratio = 4.23, P = .04) and 0–12 months (hazard ratio = 2.41, P = .022) was the only significant MR imaging predictor of time to confirmed disability progression. CONCLUSIONS: Atrophied T2 lesion volume is a robust and early marker of disability progression in relapsing-remitting MS.Keywords
This publication has 35 references indexed in Scilit:
- Clinical Relevance of Brain Volume Measures in Multiple SclerosisCNS Drugs, 2014
- The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosisHuman Brain Mapping, 2011
- Measuring Demyelination and Remyelination in Acute Multiple Sclerosis Lesion VoxelsArchives of Neurology, 2009
- The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcomeJournal of Neurology, 2008
- Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyAnnals of Neurology, 2006
- The measurement and clinical relevance of brain atrophy in multiple sclerosisThe Lancet Neurology, 2006
- Advances in functional and structural MR image analysis and implementation as FSLNeuroImage, 2004
- Controlling the false discovery rate in behavior genetics researchBehavioural Brain Research, 2001
- T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow‐up studyEuropean Journal of Neurology, 2001
- Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopyAnnals of Neurology, 1999